The most advanced vaccine in development to protect against genital herpes disease in woman, GlaxoSmithKline's Simplirix, has unexpectedly failed in a large Phase III trial, leading the company to discontinue its development.
The Herpevac Trial for Women was conducted collaboratively with the US National Institute of Allergy and Infectious Diseases (NIAID), part...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
